Cubist Systematic Strategies, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.

Quarter-by-quarter ownership
Cubist Systematic Strategies, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$444,822
-45.4%
9,800
-32.4%
0.00%
-50.0%
Q2 2023$814,030
-28.7%
14,500
-42.5%
0.01%
-14.3%
Q1 2023$1,141,424
-83.3%
25,236
-85.0%
0.01%
-82.5%
Q4 2022$6,846,558
+981.6%
168,427
+1638.3%
0.04%
+900.0%
Q3 2022$633,000
-74.3%
9,689
-76.1%
0.00%
-73.3%
Q2 2022$2,461,000
+26.3%
40,492
+30.4%
0.02%
-6.2%
Q1 2022$1,949,000
-13.6%
31,051
+4.2%
0.02%
-23.8%
Q4 2021$2,257,000
+230.9%
29,786
+388.5%
0.02%
+133.3%
Q3 2021$682,000
-68.6%
6,097
-54.6%
0.01%
-64.0%
Q2 2021$2,174,000
+339.2%
13,427
+230.7%
0.02%
+316.7%
Q1 2021$495,000
-93.3%
4,060
-91.6%
0.01%
-94.1%
Q4 2020$7,401,000
+115.6%
48,338
+17.8%
0.10%
+100.0%
Q3 2020$3,432,000
+280.9%
41,037
+234.7%
0.05%
+218.8%
Q2 2020$901,000
+56.4%
12,260
-9.7%
0.02%0.0%
Q1 2020$576,000
-79.9%
13,570
-71.2%
0.02%
-69.8%
Q4 2019$2,871,000
+1048.4%
47,140
+672.8%
0.05%
+960.0%
Q3 2019$250,000
-25.8%
6,100
-14.7%
0.01%
-16.7%
Q2 2019$337,000
+296.5%
7,150
+200.0%
0.01%
+100.0%
Q1 2019$85,000
-92.5%
2,383
-94.0%
0.00%
-94.3%
Q4 2018$1,130,000
+400.0%
39,550
+677.8%
0.05%
+341.7%
Q3 2018$226,0005,0850.01%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q2 2021
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$27,989,04633.20%
Gilfoyle Management LLC 100$4,84215.90%
NEA Management Company, LLC 1,587,854$89,142,1246.80%
ARK Investment Management 7,338,447$411,980,3942.73%
Nikko Asset Management Americas, Inc. 3,533,357$198,327,3282.09%
Del-Sette Capital Management, LLC 33,661$1,889,7291.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Ikarian Capital, LLC 200,000$11,228,0001.79%
Merlin Capital, Inc 8,802$494,1441.67%
Green Alpha Advisors, LLC 34,373$1,929,7001.27%
View complete list of CRISPR THERAPEUTICS AG shareholders